Vaccines and Neurological Disease

Author(s): Hsiuying Wang.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 43 , 2019

Become EABM
Become Reviewer

[1]
Hofmann C, Baur MO, Schroten H. Anti-nmda receptor encephalitis after tdap-ipv booster vaccination: Cause or coincidence? J Neurol 2011; 258(3): 500-1.
[2]
Wang H. Anti-nmda receptor encephalitis and vaccination. Inter J Mol Sci 2017; 18(1) pii: E193
[3]
Wang H. A protocol for investigating the association of vaccination and anti-nmda receptor encephalitis. Front Biosci 2018; 10: 229-37.
[4]
Shim B-S, Wu W, Kyriakis CS, et al. Microrna-555 has potent antiviral properties against poliovirus. J Gen Virol 2016; 97(3): 659-68.
[5]
Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol 2001; 2(9): 762.
[6]
Nakashima S, Nacher JC, Song J, Akutsu T. An overview of bioinformatics methods for analyzing autism spectrum disorders. Curr Pharm Des 2019; 25(43): 4552-9.
[7]
Lee Y, Lee BH, Yip W, Chou P, Yip B-S. Neurofilament protein as biomarker in different neurological disorder. Curr Pharm Des 2019; 25(43): 4560-9.
[8]
Tian MYJ, Li L, Li J, Lei W, Shu X. Vaccine associated neurological adverse events: a case report and mini review of literatures. Curr Pharm Des 2019; 25(43): 4570-8.
[9]
Wang H. Anti-nmda receptor encephalitis, vaccination and viruses. Curr Pharm Des 2019; 25(43): 4579-88.
[10]
Taguchi YH, Turki T. Neurological disorder drug discovery from gene expression with tensor decomposition. Curr Pharm Des 2019; 25(43): 4588-99.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 43
Year: 2019
Page: [4551 - 4551]
Pages: 1
DOI: 10.2174/138161282543191230123014

Article Metrics

PDF: 15
HTML: 3